FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
PM-TRPV4 positivity associated with invasive progression in patients with ductal carcinoma in situ
New Protein Test Predicts Which Breast Lesions Spread
This retrospective case-control study evaluated 44 patients with pure ductal carcinoma in situ (DCIS) to assess PM-TRPV4 status.
A new protein test on cell walls helps doctors predict which early breast changes might spread to invasive cancer.
Combining chemotherapy, immunotherapy, and high-dose radiation achieved remission in a patient with cervical esophageal adenocarcinoma
Rare throat cancer vanishes after bold three-pronged treatment
This case report describes a 39-year-old male with cervical esophageal adenocarcinoma treated with standard chemotherapy and immunotherapy c…
A 39-year-old man with rare throat cancer reached complete remission after doctors combined chemo, immunotherapy, and high-dose radiation.
Meta-analysis finds TSP-9 test predicts progression to HGD/EAC in Barrett's esophagus
TSP-9 test predicts disease progression in Barrett's esophagus patients with high accuracy
A systematic review and meta-analysis of 699 patients with Barrett's esophagus found the Tissue Systems Pathology (TSP-9) test was associate…
A new test for Barrett's esophagus accurately predicts who is at high risk of developing serious esophageal cancer, helping doctors focus ca…
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.
Research across Cancer
Related studies from across the Cancer family.
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Questions about Esophageal Adenocarcinoma
Does neoadjuvant chemoradiation improve resection rates for esophageal adenocarcinoma patients?
For esophageal adenocarcinoma, neoadjuvant chemoradiation does not improve overall resection rates but does increase R0 (margin-negative) resection rates compared to chemotherapy alone.
Full answer →Is pathologic complete response a good predictor of survival for esophageal adenocarcinoma?
Yes, for esophageal adenocarcinoma, achieving a pathologic complete response after neoadjuvant therapy is strongly linked to better survival, especially in certain subgroups.
Full answer →Does OPDIVO QVANTIG help treat esophageal adenocarcinoma?
OPDIVO QVANTIG is not currently approved for esophageal adenocarcinoma, but the active drug inside it, nivolumab, is proven to help treat this cancer when combined with chemotherapy.
Full answer →